drugset / Trial / NCT02341014
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Phase 1/2
Completed
27 enrolled
Memorial Sloan Kettering Cancer Center
University of Nebraska · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.
Timeline
- Start
- 2015-01-02
- Primary completion
- 2023-01-11
- Completion
- 2023-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 20 mg/m2 | — |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Romidepsin | Peptide | — | Intravenous |